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The present study offers a meta-analysis of published randomized controlled trials (RCTs) evaluating the outcomes
of in vitro fertilization (IVF) cycles using corifollitropin alfa for controlled ovarian stimulation (COS) in comparison
with daily recombinant FSH (rFSH). The study examined seven RCTs including 2138 patients receiving corifollitropin
alfa and 1788 women receiving daily rFSH for COS. As a novel aspect, this meta-analysis included two specific
subpopulations of IVF patients, i.e. egg donors and poor responders. There were no significant differences between
corifollitropin alfa and rFSH with respect to the majority of the clinical parameters considered, and comparable were
the outcomes in terms of live birth rate, ongoing pregnancy rate, and clinical pregnancy rate. Women receiving
corifollitropin alfa had a significantly higher number of metaphase II oocytes at ovum pick-up, and number of
formed embryos, in comparison to rFSH. The risk of cycle cancellation due to overstimulation was significantly
higher in the corifollitropin alfa group. Ovarian hyperstimulation syndrome (OHSS) incidence was statistically
comparable between patients receiving long lasting or daily rFSH. Nevertheless, in view of the fact that
corifollitropin alfa resulted in a higher number of metaphase II oocytes collected and a higher number of cycles
cancelled due to overstimulation, corifollitropin alfa should be cautiously considered in women with the potential
of being hyper responders.
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reproductive technologies, Meta-analysisIntroduction
In recent years, attention has been increasingly paid - in
the field of IVF - to the development of simplified treat-
ment approaches with the aim of reducing treatment
burden and to prevent drop-out rate after a failed IVF
cycle [1–3].
Corifollitropin alfa is a novel recombinant fertility hor-
mone with prolonged follicle-stimulating activity used
for COS in IVF [4]. A single subcutaneous injection of
corifollitropin alfa has the capacity to initiate and sustain
multiple follicular growth for the first seven days of
COS, thus reducing the number of injections required
during one treatment cycle [4, 5]. The long-acting proper-
ties of this new drug have been obtained by incorporating* Correspondence: tiboni@unich.it
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creativecommons.org/publicdomain/zero/1.0/the carboxy-terminal peptide from the beta subunit of
human chorionic gonadotropin (hCG) to the beta subunit
of FSH [6, 7]. As unique pharmacokinetic properties, cori-
follitropin alfa displays a slower absorption and a longer
elimination half-time in comparison to rFSH. Corifollitro-
pin alfa has indeed a time interval to peak serum levels
that is almost 4-fold longer, and the elimination half-time
(approximately 69 h) that is about two-fold longer than
the conventional rFSH [4, 5, 8]. Corifollitropin alfa has
identical pharmacodynamics properties to rFSH since it
interacts exclusively with the FSH receptor and is devoid
of LH activity [5]. Based on pharmacokinetics studies and
modeling [7, 9], the optimal corifollitropin doses have
been identified to be: 100 μg in women who weigh less
than or equal to 60 kg and who are 36 years of age or
younger; 150 μg in women who weigh more than 60 kg
regardless of age and women who weigh 50 kg or more
and who are older than 36 years of age. The effectivenessarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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have been the subject of several randomized controlled
trials (RCTs). Previous meta-analyses [10, 11] have
performed analysis on studies published up to 2011. The
present paper aims to provide an updated meta-analysis
on the corifollitropin alfa in IVF.Meterials and methods
Search strategy
A systematic search of the electronic literature through
MEDLINE and EMBASE databases was performed to
identify studies published between 2001 and December
2014. The following headings and text strings were used
alone or in combination: corifollitropin alfa, long acting
FSH, in vitro fertilization, assisted reproductive technolo-
gies, in vitro fertilization-embryo transfer, intracytoplasmic
sperm injection (ICSI). In addition, the Google Scholar
database was similarly searched for studies related to cori-
follitropin alfa. A reference list of all included manuscripts
and reviewers related to corifollitropin alfa was manually
searched for additionally potentially eligible studies. Rele-
vant journals and symposia proceedings were also evalu-
ated to identify additional data. There was no language
restriction.Fig. 1 Study flow diagramSelection criteria and data extraction
Two reviewers performed data extraction and evaluation
of trial quality independently. Any disagreement con-
cerning the extracted data was resolved by consensus
and, if necessary, by involving a third reviewer. Only
randomized controlled trials that compared the clinical
effectiveness and safety of corifollitropin alfa with rFSH
were deemed eligible for inclusion in the meta-analysis.
Publications were scrutinized to identify study character-
istics, randomization, allocation, blinding, and intention-
to-treat analysis. Excluded studies included retrospective
and uncontrolled studies, editorials and reviews. The
search results were cross-checked against papers consid-
ered in previous meta-analyses [10, 11]. The target
population was composed of infertile couples with any
infertility factor undergoing to IVF/ICSI or egg donors,
with the therapeutic intervention being corifollitropin
alfa versus rFSH. The considered outcome measures
were ongoing pregnancy rate, live birth and clinical
pregnancy rate, early miscarriage rate, number of meta-
phase II oocytes per oocyte pick-up, number of embryos
obtained and fertilization rate per woman with intracyto-
plasmic sperm injection, incidence of OHSS, adverse
events, cycle cancellation and total duration. All out-
comes were defined before undertaking the literature
search. If additional information was required, the corre-
sponding authors were contacted.Statistical analysis
Concerning the measures of the treatment effect, the
present study considered both dichotomous and con-
tinuous data. As for the first, the results in the control
and intervention groups of each study were expressed as
Peto odds ratios (OR) with 95 % confidence intervals
(CI). Continuous outcomes were expressed as weighted
mean differences (WMD) with 95 % confidence intervals
as well. The data were treated using fixed or random
effects model. Heterogeneity of treatment effects was
statistically evaluated by Hotelling T-square (τ2), Hig-
gins (I2), Birge’s ratio (H2), and Chi-square test (Chi2).
A P-value < 0.05 referred to the overall effect was con-
sidered statistically significant. Statistical analysis was
carried out using the package Metafor, version 1.9–3, a
free and open-source add-on for conducting meta-
analyses with the statistical software environment R.
Results
The search yielded 51 studies of which 44 were excluded
by screening through titles and abstracts (Fig. 1). Full
manuscripts were retrieved for the remaining papers that
included 6 full texts published in peer reviewed journals,
and 1 abstract from the annual meeting of the American
Society of Reproductive Medicine. Study characteristics
are shown in Table 1. The seven trials enrolled a total of
Table 1 Characteristics of studies included the meta-analysis of corifollitropin alfa versus recombinant FSH
Author and year Study size (n1/n2) RCT Inclusion and exclusion criteria Corifollitropin alfa protocol Recombinant FSH protocol
Devroey et al,
2009 [12]
756/750 yes Women aged 18–36 y with a body weight >60 kg
up to and including 90 kg, a BMI of 18–32 kg/m2,
a menstrual cycle length of 24-35 days, access to
ejaculatory sperm, and an indication to COS
before IVF or ICSI.
Patients started their treatment cycle on menstrual
cycle day 2 or 3. Single s.c. injection 150 μg
corifollitropin alfa, or matching placebo. From
stimulation day 8 onwards treatment was
continued with a daily s.c. of rFSH up to and
including the day of hCG administration. The
maximum rFSH dose to continue treatment after
the first 7 days was for 7 d +≤ 200 IU (from sd 8)
rFSH + GnRH antagonist (ganirelix, 0.25 mg). 5000–
10,000 IU urinary hCG. Progesterone ≥600 mg/d
vaginally or at least 50 mg/d IM.
Placebo + 200 IU rFSH + 200 IU (from sd 8) rFSH +
GnRH antagonist (ganirelix, 0.25 mg). 5000–
10,000 IU urinary hCG. P ≥600 mg/d vaginally or
at least 50 mg/d IM.
Exclusion criteria: endocrine abnormality,
abnormal blood biochemistry or hematology,
abnormal cervical smear, chronic disease, relevant
ovarian, tubal or uterine pathology that could
interfere with COS embryo implantation or
pregnancy, history of ovarian hyper-response (>30
follicles >11 mm) or OHSS, PCOS, or basal AFC
>20 on ultrasound, or women with history of low
ovarian response to FSH or hMG treatment, basal
FSH or LH >12 IU/L in early follicular phase, >3
consecutive unsuccessful IVF cycles, history of ≥3
recurrent miscarriages, smoking >5 cigarettes per
day.
Ensure, 2010 [14] 268/128 yes Women aged 18–36 y with body weight ≤60 kg,
BMI 18–32 kg/m2, normal menstrual cycle length
(24–35 days).
Single injection 100 μg corifollitropin alfa SC +
placebo for 7 d +≤ 200 IU (from sd 8) rFSH +
GnRH antagonist (ganirelix, 0.25 mg). 5000–
10,000 IU urinary hCG. Progesterone ≥600 mg/d
vaginally or at least 50 mg/d IM.
Placebo + 200 IU rFSH (follitropin beta) +≤200 IU
(from sd 8) rFSH + GnRH antagonist (ganirelix,
0.25 mg). 5000–10,000 IU urinary hCG.
Progesterone ≥600 mg/d vaginally or ≥50 mg/d






242/83 yes Women aged 20–39 y with a normal menstrual
cycle (24–35 days) and a BMI 17–31 kg/m2.
Single SC dose of 60, 120, or 180 μg corifollitropin
alfa + 150 IU (from sd 8) rFSH (follitropin beta) +
GnRH antagonist (ganirelix, 0.25 mg) up to the day
of hCG administration (10,000 IU). Daily
progesterone to support luteal phase.
150 IU rFSH + GnRH antagonist (ganirelix, 0.25 mg)
up to the day of hCG administration (10,000 IU)
10,000 IU hCG. Daily progesterone to support
luteal phase.Exclusion criteria: history of OHSS, PCOS, or any
endocrine abnormality, previous poor response to
FSH or hMG, more than 3 unsuccessful COS
cycles, fewer than 2 ovaries, abnormal hormone
levels during days 2–7 of menstrual cycle, use of
hormonal preparations within 1 month before
treatment or previous use of corifollitropin alfa.
Devroey et al.,
2004 [15]
75/24 yes Women aged 18–39 y, BMI 18–29 kg/m2, with a
regular menstrual cycle (24–35 days).
Single SC dose of corifollitropin alfa) of 120, 180,
or 240 μg followed one week later by 150 IU rFSH
+ GnRH antagonist (ganirelix, 0.25 mg). 10,000 IU
of hCG. Vaginal micronized P (600 mg/d) or IM P
(≥50 mg/d).
150 IU rFSH + GnRH antagonist (ganirelix, 0.25 mg)
starting on the day that the leading follicle had
reached 14 mm. 10,000 IU urinary hCG. Vaginal
micronized P (600 mg/d) or IM progesterone
(≥50 mg/d).
Exclusion criteria: Not indicated
Requena et al.,
2013 [3]
63/68 yes Oocyte donors aged 18-35 y with a regular
menstrual cycle, no hereditary or chromosomal
diseases, normal karyotype, at least 7 antral
follicles at the beginning of the cycle, body
weight ≥60 kg and BMI ≤29 kg/m2.
Oral contraceptive pill for a maximum of 21 days
preceded ovarian stimulation. Single injection
150 μg corifollitropin alfa. From stimulation day 8
onwards treatment was continued with a daily s.c.
of rFSH 200 IU if needed. GnRH antagonist
(ganirelix, 0.25 mg). A single dose of GnRH agonist
(0.1 mg Decapeptyl) to trigger final oocyte
maturation.
Oral contraceptive pill for a maximum of 21 days
preceded ovarian stimulation. 200 IU rFSH + GnRH
antagonist (ganirelix, 0.25 mg). A single dose of
GnRH agonist (0.1 mg Decapeptyl) to trigger final
oocyte maturation
Exclusion criteria: Oocyte donors who had PCOS













Table 1 Characteristics of studies included the meta-analysis of corifollitropin alfa versus recombinant FSH (Continued)
Kolibianakis
et al., 2015 [16]
40/39 yes Women poor responder aged <45 y.
Characteristics of corifollitropin alfa versus daily
FSH group: mean age (40.1 ± 3.3 vs. 40.1 ±
3.7 years, respectively; p = 0.96), mean BMI
(26.1 ± 3.4 vs. 26.2 ± 3.5 Kg/m2, respectively;
p = 0.95), mean basal FSH (12.3 ± 4.6 vs.
11.1 ± 3.2 IU/L, respectively; p = 0.46).
Single dose of 150 μg (0.5 mL) corifollitropin alfa
+ GnRH antagonist (from sd 5 onwards) until hCG
+ 250 μg of rehCG + daily dose of recFSH (450 IU/
day) (from sd8 until the day of hCG, if necessary)
+ vaginal micronized progesterone (600 mg/day).
Previous IVF cycle with a starting dose of at least
450 IU per day + GnRH antagonist (from sd5
onwards) until hCG + 250 μg of rehCG + daily
dose of recFSH (450 IU/day) (from sd8 until the





694/696 yes Women aged 35–42 years. During the first 7 days of ovarian stimulation,
single injection of 150 μg CFA. When required,
they continued the cycle with daily rFSH
(maximally 300 IU) until 3 follicles reached
≥17 mm. Ganirelix acetate (0.25 mg) was started
on stimulation day 5 and recombinant human
chorionic gonadotropin was given to trigger
oocyte maturation. Three days after oocyte
pick-up, 2 embryos were transferred.
Daily 300 IU rFSH for 7 days. When required, they
continued the cycle with daily rFSH (maximally
300 IU) until 3 follicles reached ≥17 mm. Ganirelix
acetate (0.25 mg) was started on stimulation day
5 and recombinant human chorionic
gonadotropin was given to trigger oocyte
maturation. Three days after oocyte pick-up,
2 embryos were transferred.
Note: CFA corifollitropin alfa; AFC antral follicle count; BMI body mass index; COS controlled ovarian stimulation; CTP C-terminal peptide; IM intramuscular; MII metaphase II; OHSS ovarian hyperstimulation syndrome;
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women. In total, 2138 women were randomized to receive
corifollitropin alfa and 1788 were randomized to receive
daily rFSH. Results offered by the meta-analysis are shown
in Fig. 2, A-K. There were differences in patient characteris-
tics and selection. In the Engage study [12, 13] women aged
18–36 years, had a body mass index (BMI) of 18–32 kg/m2
and weighed 61–90 kg. In the Ensure trial [14], participants
aged 18–36 years with a body weight ≤ 60 kg. In both
Engage and Ensure trials patients with a history of ovarian
hyper response to ovarian stimulation (more than 30
follicles ≥ 11 m) or OHSS, polycystic ovarian syndrome
(PCOS) or more than 20 basal antral follicles on ultrasound
(<11 mm, both ovaries combined) were excluded from the
study. Women with a history of poor ovarian response were
also excluded in both studies. In the Corifollitropin Alfa
Dose-finding Study Group [9], patients were women aged
20–39 years with a BMI of 17–31 kg/m2 . In the Devroey
et al. study [15], participants were between 18 and 39 year
of age and a BMI 18–29 kg/m2). Patients with a history of
OHSS, PCOS or poor response, were excluded. In the
Requena et al. study [3], the oocyte donors included in the
study aged 18–35 years, had regular menses and had a body
weight > 60 kg with a BMI up to 29 kg/m2 with at least
seven antral follicles at the beginning of the cycle. Donors
having PCOS or multifollicular ovaries were excluded. The
study of Kolibianakis et al. [16] included patients with
previous poor ovarian response defined as retrieval of ≤4
COCs in a previous IVF cycle in which a starting dose of at
least 450 IU per day was used, age <45 years, regular spon-
taneous menstrual cycle (24–35 days), body mass index
(BMI) of 18–32 kg/m2 and basal FSH ≤20 IU/l. Differences
among studies may represent sources of biases and, as it
will be discussed later, influenced the result in terms of
heterogeneity.
Pooling the results of these seven RCTs, there was no
significant difference in terms of live birth rate (4 RCTs;
OR 1.12, 95 % CI 0.96–1.31; P = .15; substantial hetero-
geneity: I2 = 70.09 %), clinical pregnancy rate (4 RCTs;
OR 1.01, 95 % CI 0.84–1.20; P = .95; moderate heterogen-
eity: I2 = 40.43 %), and ongoing pregnancy rate (6 RCTs;
OR 1.04, 95 % IC 0.90–1.20; P = .62; substantial hetero-
geneity: I2 = 63.40 %) between the two groups. Four stud-
ies reported the early miscarriage rate per randomized
woman. No significant difference was found in this respect
between patients treated with corifollitropin alfa and daily
rFSH (4 RCTs; OR 1.20, 95 % CI 0.75–1.92; P = .45; low
heterogeneity: I2 = 1.53 %). A significantly higher number
of embryos was obtained in women treated with corifolli-
tropin alfa if compared to the rFSH group (6 RCTs; WMD
0.77, 95 % CI 0.41–1.13; P < .0001; substantial heterogen-
eity: I2 = 67.21 %, H2 = 3.05). No significant difference was
observed in the mean duration of stimulation (4 RCTs;
WMD 0.36, 95 % CI −0.36–1.09; P = .32; considerableheterogeneity: I2 = 85.42 %, H2 = 6.86). Regarding the
number of oocytes, meta-analysis of the six RTCs demon-
strated a significantly higher number of oocytes retrieved
in the corifollitropin alfa group in comparison to the daily
rFSH group (7 RCTs; WMD 1.37, 95 % CI 0.58–2.16;
P = .0007; substantial heterogeneity: I2 = 76.65 %, H2 =
4.28). Data relative to the number of mature (MII) oocytes
were reported by the six RTCs. Overall, there was a sig-
nificantly higher number of mature oocytes (MII) in the
corifollitropin alfa in comparison to rFSH (6 RCTs; WMD
1.54, 95 % CI 0.66–2.43; P = .0006; substantial heterogen-
eity: I2 = 67.21 %, H2 = 6.23). Cancellation of the cycle due
to low response (3 RCTs; OR 1.08, 95 % CI 0.69–1.67;
P = .74; no heterogeneity: I2 = 0 %) was comparable
between the two groups. Cycle cancellation due to high
response (3 RCTs; OR 3.19, 95 % CI 1.07–9.45; P = .03;
moderate heterogeneity: I2 = 44.24 %) was significantly
higher in the corifollitropin alfa group than in daily rFSH
group. The incidence of OHSS was comparable between
the two study groups (5 RCTs; OR 1.03, 95 % CI 0.74–
1.45; P = .84; no heterogeneity: I2 = 0 %).
Discussion
Controlled ovarian stimulation for IVF has relied, since
its introduction, on daily administration of various for-
mulations of gonadotropins. A single injection of the
long lasting FSH corifollitropin alfa can replace the first
standard seven daily injections of gonadotropins. This
may result, in line with current expectations in IVF, in a
simplification of the treatment regimen and reduced
treatment burden [1–3]. Corifollitropin alfa is adminis-
tered as a single injection during menstrual cycle days 2
or 3 (stimulation day 1). Daily injections of FSH are
started on stimulation day 8 if needed. A gonadotropin
releasing hormone antagonist is associated starting on
stimulation day 5 to prevent premature LH surge. In the
current study, available RCTs were included in a meta-
analysis comparing corifollitropin alfa with conventional
daily injections of FSH in IVF patients. A substantial
amount of data derived from two large phase III ran-
domized, double dummy, double blind trials designed by
the manufacturer, and including patient less than
36 years that were considered not at risk of developing
OHSS (antral follicle count ≤ 20). There were 756
women weighting > 60 kg that received corifollitropin
alfa at 150 μg [12, 13], and 268 with a body weight ≤
60 kg that received 100 μg [14]. Results were compared
with reference groups receiving daily injections of rFSH
at 150 IU [15] or 200 IU [12, 13]. The Corifollitropin
Alfa Dose Finding Study Group [8], a phase II study
including 325 women, was undertaken to investigate the
dose–response relationship with respect to the number
of oocytes retrieved after administration of corifollitro-
pin alfa at 60, 120 or 180 μg. Devroey et al. [15], in their
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(n = 25), 180 μg (n = 24), or 240 μg (n = 25) corifollitro-
pin alfa or 150 IU of daily rFSH. The follow-up trial is a
phase 3 randomized, double-blind, double-dummy,
active-controlled, noninferiority trial, including women
aged 35–42 years [17]. 1390 women were randomized to
a single injection of 150 μg corifollitropin alfa (n = 694)
or daily 300 IU rFSH during the first seen days of ovar-
ian stimulation. A GnRH antagonist was started on
stimulation day 5. When required, ovarian stimulation
was continued with daily injections of rFSH at the max-
imal dose of 300 IU. As result, corifollitropin alfa was
found to be non-inferior to rFSH in terms of effective-
ness. Requena and co-workers [3] evaluated the degree
of satisfaction in oocyte donors undergoing treatment
with corifollitropin alfa (n = 48) compared with women
receiving rFSH (n = 40). The study involved patients
weighting more than 60 kg and thus receiving corifolli-
tropin alfa at 150 μg. Assignment to each treatment
group was made according to a quasi-experimental de-
sign which included consecutive opportunity sampling.
Patients were pre-treated with an oral contraceptive pill
before starting COS. Potential high responders were ex-
cluded. Moreover, to further reduce the risk of OHSS,
GnRH agonist (instead of hCG) was used to trigger final
oocyte maturation. The study carried out by Kolibianakis
by et al. [16], included seventy-nine women and aimed
to evaluate the potential benefit of corifollitropin alfa
treatment compared to daily rFSH in poor responder
patients. In this prospective, randomized, open label,
non-inferiority clinical trial, women were considered
poor responders if they had a previous poor response to
ovarian stimulation. Other inclusion criteria were: age
less than 45; regular menses; body mass index (BMI) of
18–32 kg/m2; and basal FSH ≤20 IU/l. On day 2 of men-
ses women received either a single dose of corifollitropin
alfa at 150 μg. When needed, 450 IU of rFSH were given
from day 8 of stimulation up the hCG day. Results were
compared with control groups receiving daily injections
of rFSH at 450 IU. As a major finding, the number of
cumulus oocyte complex that were recovered was not
statistically different between the corifollitropin alfa and
rFSH groups.
Pooling data from these studies showed no significant
differences in the majority of clinical parameters consid-
ered between corifollitropin alfa and rFSH. This meta-
analysis revealed comparable outcomes in terms of live
birth rate, ongoing pregnancy rate and clinical preg-
nancy rate. Pregnancies obtained in women undergoing
COS with corifollitropin alfa had the same risk of spon-
taneous abortion as pregnancies from rFSH. When the
ovarian response to COS was considered, corifollitropin
alfa yielded a higher number of oocytes than rFSH. In
line with this finding, the number of embryos obtainedper woman randomized in the corifollitropin alfa group
was also higher. These outcomes, along with the evi-
dence that a higher number of women treated with this
drug experienced cycle cancellation due to overstimula-
tion, underscore the need for a careful selection of the
patients that are eligible for corifollitropin alfa in order
to prevent OHSS. However, the major ovarian response
associated to COS with corifollitropin alfa did not result
in a statistically significant increased risk of OHSS.
When discussing the risk of OHSS, it appears important
to consider the criteria for cycle cancellation used. These
are available for the Ensure and Engage RTCs. In both
studies, the investigator was allowed to withhold rFSH
administration for a maximum of 3 days. When the
investigator considered the ovarian response too high,
he was allowed to cancel the cycle at any time. In the
case of a risk for OHSS (more than 30 follicles > 11 m
on ultrasound scan) hCG was to be withheld and the
treatment cycle would be cancelled. The Kolibianakis
et al. [16] study compared corifollitropin alfa with rFSH
in poor responder patients. Thus, there was no risk of
OHSS. There were no significant differences with
respect of length of stimulation associated to corifollitro-
pin alfa in comparison to rFSH. Corifollitropin alfa has
been designed to relieve the treatment burden experi-
enced by IVF women. Results offered by the pooled ana-
lysis of this meta-analysis are compatible with the notion
that proper exposure to corifollitropin alfa results in IVF
outcome comparable to that observed with rFSH. This
concept is in line with conclusions provided by two
previously published meta-analyses [10, 11]. As a novel
aspect, this meta-analysis included RCTs on two specific
subpopulations of IVF patients, i.e. egg donors [3] and
poor responders [16]. Conclusions of our meta-analysis
could be slightly different when separately considering
these subpopulations. Unfortunately, the number of this
type of studies is not sufficient to perform a population-
specific meta-analysis. This circumstance is reflected by
moderately higher levels of heterogeneity, as seen in the
previous section. To satisfyingly detect it, we need to
consider that H2 indexes in the above experiments are
always significantly bigger than one, and this is sign of
strong diversity between groups. The resulting analysis
may be thus more reflective of the everyday clinical
practice. Also consider that at the time of writing only a
limited number of RCTs was available. This represented
a major limitation of this meta-analysis. For instance we
were unable to analyze publication bias using funnel
plots, since it is known that at least ten RCTs are re-
quired to get statistically significant results [18]. A con-
cept that must be born in mind when using
corifollitropin alfa is that its unique pharmacokinetic
profile can result in the recruitment of an increased co-
hort of developing follicles, and this contraindicates its
Fensore et al. Journal of Ovarian Research  (2015) 8:33 Page 8 of 8use in high responder patients that are at risk of OHSS.
Adequate definition of the ovarian reserve and thus ex-
clusion of patients with high ovarian reserve appears to
remain a crucial step before considering long lasting
FSH for COS.
Conclusions
Corifollitropin alfa was designed to simplify the treatment
regimen in patients undergoing ovarian stimulation for
IVF. This systematic review and meta-analysis suggests
that corifollitropin alfa is effective as rFSH in terms of live
birth rate, ongoing pregnancy rate and clinical pregnancy
rate. The increased number of eggs retrieved under cori-
follitropin alfa regimen reflects the elevated effectiveness
of this novel FSH formulation, but warns at the same time
against the possible increased risk of OHSS in high
responder women.
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